Journal of Clinical Oncology, Vol 16, 3744-3751, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group

DM Green, NE Breslow, JB Beckwith, JZ Finklestein, P Grundy, PR Thomas, T Kim, S Shochat, G Haase, M Ritchey, P Kelalis and GJ D'Angio
Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. green@sc3101.med.buffalo.edu

PURPOSE: National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of the administration of different regimens for the treatment of Wilms' tumor (WT). PATIENTS AND METHODS: Between August 6, 1986 and September 1, 1994, 905 previously untreated children aged younger than 16 years with stage II favorable histology (FH) WT (low-risk [LR]), stages III to IV FH WT, or stages I to IV clear-cell sarcoma of the kidney (high-risk[HR]) were randomized after the completion of 6 months of chemotherapy to discontinue (short) or continue for 9 additional months (long) treatment with chemotherapy regimens that included vincristine and either divided-dose (standard [STD]) courses (5 days) or single-dose (pulse-intensive [PI]) treatment with dactinomycin. HR patients also received either divided-dose (STD) courses (3 days) or single-dose (PI) treatment with doxorubicin. RESULTS: The 4-year relapse-free survival (RFS) rates after the second randomization for LR patients were 83.7% for the 190 patients treated with short and 88.2% for the 187 patients treated with long chemotherapy (P = .11). The 4-year RFS rates after the second randomization for HR FH patients were 89.7% for the 256 patients treated with short and 88.8% for the 246 patients treated with long chemotherapy (P = .87). The charge for treatment with the short PI treatment regimens for all children with stages I through IV FH WT was approximately one half of that with the long STD treatment regimens. CONCLUSION: The short administration schedule for the treatment of children with WT is no less effective than the long administration schedule and can be administered at a substantially lower total treatment cost.

This article has been cited by other articles:

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				G. E. Tomlinson, N. E. Breslow, J. Dome, K. A. Guthrie, P. Norkool, S. Li, P. R.M. Thomas, E. Perlman, J. B. Beckwith, G. J. D'Angio, et al. Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor J. Clin. Oncol., October 20, 2005; 23(30): 7641 - 7645. [Abstract] [Full Text] [PDF]

				P. E. Grundy, N. E. Breslow, S. Li, E. Perlman, J. B. Beckwith, M. L. Ritchey, R. C. Shamberger, G. M. Haase, G. J. D'Angio, M. Donaldson, et al. Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., October 10, 2005; 23(29): 7312 - 7321. [Abstract] [Full Text] [PDF]

				G. J. Veal, M. Cole, J. Errington, A. Parry, J. Hale, A. D.J. Pearson, K. Howe, J. C. Chisholm, C. Beane, B. Brennan, et al. Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study Clin. Cancer Res., August 15, 2005; 11(16): 5893 - 5899. [Abstract] [Full Text] [PDF]

				N. L. Seibel, S. Li, N. E. Breslow, J. B. Beckwith, D. M. Green, G. M. Haase, M. L. Ritchey, P. R.M. Thomas, P. E. Grundy, J. Z. Finklestein, et al. Effect of Duration of Treatment on Treatment Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., February 1, 2004; 22(3): 468 - 473. [Abstract] [Full Text] [PDF]

				K. Pritchard-Jones, A. Kelsey, G. Vujanic, J. Imeson, C. Hutton, and C. Mitchell Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms' Tumor Treated With Vincristine Monochemotherapy: A Study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group J. Clin. Oncol., September 1, 2003; 21(17): 3269 - 3275. [Abstract] [Full Text] [PDF]

				K Pritchard-Jones Controversies and advances in the management of Wilms' tumour Arch. Dis. Child., September 1, 2002; 87(3): 241 - 244. [Abstract] [Full Text] [PDF]

				D. M. Green, E. M. Peabody, B. Nan, S. Peterson, J. A. Kalapurakal, and N. E. Breslow Pregnancy Outcome After Treatment for Wilms Tumor: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., May 15, 2002; 20(10): 2506 - 2513. [Abstract] [Full Text] [PDF]

				D. M. Green, N. E. Breslow, J. B. Beckwith, M. L. Ritchey, R. C. Shamberger, G. M. Haase, G. J. D'Angio, E. Perlman, M. Donaldson, P. E. Grundy, et al. Treatment With Nephrectomy Only for Small, Stage I/Favorable Histology Wilms' Tumor: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., September 1, 2001; 19(17): 3719 - 3724. [Abstract] [Full Text] [PDF]

				D. M. Green, Y. A. Grigoriev, B. Nan, J. R. Takashima, P. A. Norkool, G. J. D'Angio, and N. E. Breslow Congestive Heart Failure After Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., April 1, 2001; 19(7): 1926 - 1934. [Abstract] [Full Text] [PDF]

				A. Eggert, M. A. Grotzer, N. Ikegaki, H. Zhao, A. Cnaan, G. M. Brodeur, and A. E. Evans Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilms' Tumor J. Clin. Oncol., February 1, 2001; 19(3): 689 - 696. [Abstract] [Full Text] [PDF]

				M. F. Tournade, C. Com-Nougue, J. de Kraker, R. Ludwig, A. Rey, J. M.B. Burgers, B. Sandstedt, J. Godzinski, M. Carli, R. Potter, et al. Optimal Duration of Preoperative Therapy in Unilateral and Nonmetastatic Wilms' Tumor in Children Older Than 6 Months: Results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study J. Clin. Oncol., January 15, 2001; 19(2): 488 - 500. [Abstract] [Full Text] [PDF]

				J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor Cancer Res., September 1, 1999; 59(17): 4301 - 4307. [Abstract] [Full Text] [PDF]